Obsidian Therapeutics, Inc. (OBX) company profile
OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.00−0.15 (-1.23%)
Close on Nov 20, 2026Market cap $741.28MP/E –Yield –
About Obsidian Therapeutics
Pharmaceutical Preparations, SIC 2834
Obsidian Therapeutics, Inc. is listed on Nasdaq under the ticker OBX, in the SEC industry Pharmaceutical Preparations. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Obsidian Therapeutics, Inc.
- Headquarters
- Cambridge, MA
- Address
- 1030 Massachusetts Avenue 02138
- Phone
- (781) 806-6245
- Website
- obsidiantx.com
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- OBX
- Exchange
- Nasdaq
- IPO date
- Jul 27, 2026
- Shares outstanding
- 62M, Aug 10, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2130606
- CUSIP
- 67448A106
- ISIN
- US67448A1060
- FIGI
- BBG02451DLZ2
- Share class FIGI
- BBG02451DM26
- EIN
- 42-1977778
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Madan Jagasia | Chief Executive Officer, Director | – |
| Julie B. Feder | Chief Financial Officer | – |
| Parameswaran Hari | Chief Medical Officer | – |
| Mark L. Reisenauer | Director | – |
| Maria Fardis | Director | – |
| Peter Barrett | Director | – |
| Heidi Hagen | Director | – |
| Robert W. Ross | Director | – |
| Matthew Norkunas | Director | 30,937 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 3, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 3, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 3, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 3, 2026 | Name change | Name changed from Gazelle Parent, Inc. to Obsidian Therapeutics, Inc. |
| Apr 22, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
See a number that looks wrong?